Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study

About the trial

Sponsor

Sanofi

Tested

Amlitelimab (drug), Placebo (drug)

Dates

Started 2023-09-05; completion 2026-09-22

Results posted

Not yet

This is a study of amlitelimab for the treatment of participants with moderate-to-severe asthma. The study will have a double-blind treatment period until Week 24 for each participant and an open-label treatment period where each participant will receive open-label amlitelimab from Week 24 onwards. The purpose of this study is to evaluate long-term safety, tolerability, and efficacy of amlitelimab for the treatment of adult participants with moderate-to-severe asthma who have previously been enrolled and completed the treatment period of the parent study. The study duration will be up to 156 weeks. The treatment duration will be up to 144 weeks. The number of visits will be 18.

From ClinicalTrials.gov, last updated 2026-10-02. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sanofi US Services Inc. reported $928,258 in research payments for this study in 2025 (71 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.